Catalog No.
FHD37530
Species reactivity
Human
Host species
Mouse
Isotype
IgG2a, kappa
Clonality
Monoclonal
Conjugation
Unconjugated
Target
Myeloid cell surface antigen CD33, Sialic acid-binding Ig-like lectin 3, Siglec-3, CD33, gp67, SIGLEC3
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P20138
Applications
FCM
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 0.09% Sodium azide.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
SAA1404
Anti-CD33 antibody enhances liposomal co-delivery of cytarabine and daunorubicin for targeted combination chemotherapy., PMID:40449802
Monoclonal Antibodies Against Myeloid Leukemia Cells: Current Knowledge and Future Directions., PMID:40429716
Multiplex base editing to protect from CD33 directed drugs for immune and gene therapy., PMID:40425554
KK2845, a PBD dimer-containing antibody-drug conjugate targeting TIM-3-expressing AML., PMID:40404985
Multiplex immunophenotyping of human acute myeloid leukemia patients revealed single -cell heterogeneity with special attention on therapy sensitive and therapy resistant subpopulations., PMID:40313947
Generation of a Severe Hemophilia A Humanized Mouse Model Capable of Inducing an Anti-FVIII Immune Response., PMID:40300593
CD33-D2 isoform characterization for advancement of its therapeutic potential., PMID:40272002
B-ALL with CD34 Negative and Surface Immunoglobulin Light Chain Restricted Expression., PMID:40209787
Aptamer- vs Fab-Conjugated Liposomes: A Comparative Study in Targeting Acute Myeloid Leukemia Cells., PMID:40148126
Discovery and preclinical development of a SdAb-based CAR-T technology for targeting CD33 in AML., PMID:40084273
A review of antibody-based immunotherapy clinical trials for adult acute myeloid leukemia (AML): monoclonal antibodies (mAbs) and beyond., PMID:40069930
Comparison of radiobiological effects induced by radiolabeled antibodies in human cancer cells and fungal cells., PMID:40009794
STING activation improves T-cell-engaging immunotherapy for acute myeloid leukemia., PMID:40009483
Phase 1 study of lintuzumab-Ac225 combined with CLAG-M salvage therapy in relapsed/refractory acute myeloid leukemia., PMID:39955432
BNT162b2 mRNA vaccination affects the gut microbiome composition of patients with follicular lymphoma and chronic lymphocytic leukemia., PMID:39930533
Protection of CD33-modified hematopoietic stem cell progeny from CD33-directed CAR T cells in rhesus macaques., PMID:39928955
Revolutionizing acute myeloid leukemia treatment: a systematic review of immune-based therapies., PMID:39864030
In Vitro and In Vivo Comparison of Random versus Site-Specific Conjugation of Bifunctional Chelating Agents to the CD33-Binding Antibody for Use in Alpha- and Beta-Radioimmunotherapy., PMID:39713652
Acute myeloid leukemia management and research in 2025., PMID:39656142
Evaluation of Gemtuzumab Ozogamicin and Anthracycline Dosing for Favorable Risk Acute Myeloid Leukemia., PMID:39601208
CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual-targeting antibody overcome antigen heterogeneity in AML., PMID:39571145
CD163+ Tumor-Associated Macrophage Recruitment Predicts Papillary Thyroid Cancer Recurrence., PMID:39426065
Current status and research directions in acute myeloid leukemia., PMID:39300079
Development of CD33-Targeted Dual Drug-Loaded Nanoparticles for the Treatment of Pediatric Acute Myeloid Leukemia., PMID:39235263
Targeting the membrane-proximal C2-set domain of CD33 for improved CAR T cell therapy., PMID:39224504
[Antibody-Drug Conjugate for Treating Leukemia and Lymphoma-The Present Status, Problems, and Future Development]., PMID:39191681
Real-world outcomes of intensive induction approaches in core binding factor acute myeloid leukemia., PMID:39157611
Tracking neuroinflammatory biomarkers in Alzheimer's disease: a strategy for individualized therapeutic approaches?, PMID:39080712
Gemtuzumab Ozogamicin and Stem Cell Mobilization for Autologous Stem Cell Transplantation in Favorable Risk Acute Myeloid Leukemia., PMID:39062189
A dual-targeting approach with anti-IL10R CAR-T cells engineered to release anti-CD33 bispecific antibody in enhancing killing effect on acute myeloid leukemia cells., PMID:39008193
89Zr-immunoPET-guided selection of a CD33xIL15 fusion protein optimized for antitumor immune cell activation and in vivo tumour retention in acute myeloid leukaemia., PMID:38987489
High-dose cytarabine plus gemtuzumab ozogamicin as consolidation therapy in patients with favorable- or intermediate-risk acute myeloid leukemia., PMID:38963637
Human plasma cells engineered to secrete bispecifics drive effective in vivo leukemia killing., PMID:38959896
Clinicopathological differences between T-lymphoblastic leukemia/lymphoma, early T-precursor lymphoblastic leukemia/lymphoma, and mixed-phenotype acute leukemia with T lineage: An analysis of 41 adult cases., PMID:38945375
CRISPR/Cas9 gene editing clarifies the role of CD33 SNP rs12459419 in gemtuzumab ozogamicin-mediated cytotoxicity., PMID:38853211
Azacitidine and gemtuzumab ozogamicin as post-transplant maintenance therapy for high-risk hematologic malignancies., PMID:38783125
Valrubicin-loaded immunoliposomes for specific vesicle-mediated cell death in the treatment of hematological cancers., PMID:38734740
Frequency and Aberrant CD Marker Profile of Acute Leukaemias., PMID:38720213
Safety and tolerability of AMG 330 in adults with relapsed/refractory AML: a phase 1a dose-escalation study., PMID:38712673
Control of acute myeloid leukemia and generation of immune memory in vivo using AMV564, a bivalent bispecific CD33 x CD3 T cell engager., PMID:38696390
Targeting SIGLEC15 as an emerging immunotherapy for anaplastic thyroid cancer., PMID:38652971
Heterodimerization of T cell engaging bispecific antibodies to enhance specificity against pancreatic ductal adenocarcinoma., PMID:38650005
Therapeutic plasma exchange as an intervention for gemtuzumab ozogamicin impaired hemoglobin scavenging: A case and systematic review., PMID:38647036
Targeting inhibitory Siglec-3 to suppress IgE-mediated human basophil degranulation., PMID:38593870
Targeting CD33+ Acute Myeloid Leukemia with GLK-33, a Lintuzumab-Auristatin Conjugate with a Wide Therapeutic Window., PMID:38561023
Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study., PMID:38547425
Therapeutic potential to target sialylation and SIGLECs in neurodegenerative and psychiatric diseases., PMID:38529039
First-in-human study of JNJ-67571244, a CD33 × CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome., PMID:38494922
Preclinical Characterization of the Anti-Leukemia Activity of the CD33/CD16a/NKG2D Immune-Modulating TriNKET® CC-96191., PMID:38473239
Immunophenotypic characterization of leukemic stem cells in acute myeloid leukemia using single tube 10-colour panel by multiparametric flow cytometry: Deciphering the spectrum, complexity and immunophenotypic heterogeneity., PMID:38456256
For research use only. Not for human or drug use.
